VG081821 / Vimgreen Pharma - LARVOL DELTA

VG081821: A ZM241385-Like A2A Receptor Antagonist With Significant Improvement in Pharmacokinetics. (PubMed, Drug Dev Res) - "In-vitro and in-vivo studies demonstrated VG081821's lower intrinsic clearance and superior pharmacokinetic profile compared to ZM241385. Given that more and more studies indicate that blocking A2A receptors has multiple beneficial effects, VG081821 may have the real potential to become a clinically valuable multi-indication therapeutic agent."

Journal • PK/PD data • ADORA2A

Vimgreen Completes Enrollment of Its Phase 2 Clinical Trial Evaluating VG081821AC for the Treatment of Parkinson’s Disease (PRNewswire) - "Vimgreen Pharmaceuticals...announced today the completion of enrollment of its Phase 2 clinical trial of VG081821AC...for the treatment of early-to-mid stage Parkinson's disease. A total of 150 participants have been enrolled and randomized into one of three cohorts, a high-dose VG081821 group, a low-dose VG081821 group, and a placebo group at a ratio of 1:1:1...The Phase 2 trial is to be completed in November."

Enrollment closed • Trial completion date • CNS Disorders • Parkinson's Disease